



POSTER PRESENTATION

Open Access

Gain-of-function mutation in *IFIH1* can cause both aicardi-goutières syndrome and systemic lupus erythematosus with IgA-deficiency

Lien Van Eyck^{1,2*}, Lien De Somer³, Diana Pombal^{1,2}, Simon Bornschein^{1,2}, Francis de Zegher^{3,4}, Adrian Liston^{1,2}, Carine Wouters^{1,3}

From 21st European Pediatric Rheumatology (PReS) Congress
Belgrade, Serbia. 17-21 September 2014

Introduction

Gain-of-function mutations in *IFIH1* were identified in Aicardi-Goutières syndrome (AGS), a rare neuroimmunological disorder associated with elevated levels of type I interferon and characterized by leucoencephalopathy, brain atrophy and intracranial calcifications leading to profound intellectual disability, spasticity and dystonia. *IFIH1* functions as an intracellular innate immune receptor that senses viral nucleic acids and leads to the induction of type I interferon and proinflammatory cytokines.

Objectives

We aimed to identify the underlying genetic defect in a 16-year-old girl with severe early-onset and refractory systemic lupus erythematosus (SLE), IgA-deficiency and mild lower limb spasticity without neuroradiological manifestations.

Methods

Whole-exome sequencing was performed on the index patient and her parents. Extensive immunological analysis was performed on serum and on peripheral blood mononuclear cells (PBMC) of the patient.

Results

We independently identified the same *de novo* p. Arg779His *IFIH1* mutation in a young patient with severe refractory SLE with antiphospholipid syndrome as was described in two patients with an AGS phenotype without major immunological manifestations. The index patient in our study, a girl of European Belgian

ancestry, was initially seen before the age of 1 year with frequent respiratory infections. Immunological testing revealed IgA-deficiency. By the age of 2.5 years she developed spasticity of the lower limbs, with normal cognitive and clinical development. Magnetic resonance imaging (MRI) of the brain and spine showed no abnormalities. At the age of 8 years the patient was diagnosed with SLE with secondary antiphospholipid syndrome. Clinically, she manifested arthritis, livedo rash, necrotizing cutaneous vasculitis and she developed a deep venous thrombosis. Blood analysis showed a marked inflammatory response, complement activation and highly increased levels of anti-dsDNA, anticardiolipin and anti-thyroid antibodies. Further analysis also showed elevated serum levels of interferon α and upregulation of *IFIH1* on the RNA-level in patient PBMC. Single-photon emission computed tomography (SPECT) of the brain showed no signs of intracerebral vasculitis and brain CT and MRI did not show any microcalcifications or other abnormalities. Despite systemic immunosuppressive treatment, signs of autoimmune activation remained with persistently increased levels of circulating autoantibodies and complement activation, as well as persistently elevated interferon α in serum and *IFIH1* upregulation in patient PBMC. Attempts at decreasing immunosuppressive medication were associated with disease flares. The lower limb spasticity has stabilized, cognitive functioning has remained excellent and all neuroradiological examinations have remained normal.

Conclusion

This finding adds a new gene association to Mendelian lupus and greatly extends the disease spectrum associated with mutations in *IFIH1*, ranging from AGS to SLE with

¹Microbiology and Immunology, KU Leuven, Belgium
Full list of author information is available at the end of the article

or without neuroradiological manifestations. This marked phenotypic heterogeneity, despite an identical mutation, demonstrates the importance of modifying genetic or environmental factors in type I interferon-dependent pathologies associated with mutations in *IFIH1*.

Disclosure of interest

None declared.

Authors' details

¹Microbiology and Immunology, KU Leuven, Belgium. ²Autoimmune Genetics Laboratory, VIB, Belgium. ³Pediatrics, UZ Leuven, Belgium. ⁴Development and regeneration, KU Leuven, Leuven, Belgium.

Published: 17 September 2014

doi:10.1186/1546-0096-12-S1-P309

Cite this article as: Van Eyck *et al.*: Gain-of-function mutation in *IFIH1* can cause both aicardi-goutières syndrome and systemic lupus erythematosus with IgA-deficiency. *Pediatric Rheumatology* 2014 12(Suppl 1):P309.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

